Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Appointed director
|
|
23andMe Holding Co.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/06/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Sold 38,548 shares
@ $0.8407, valued at
$32.4k
Exercised 38,548 options to buy
@ $0.42, valued at
$16.2k
|
|
| 10/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/25/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Sold 40,894 shares
@ $1.0544, valued at
$43.1k
Exercised 40,894 options to buy
@ $0.42, valued at
$17.2k
|
|
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Paid exercise price by delivering 4,628 shares
@ $1.14, valued at
$5.3k
|
|
| 08/22/2023 |
4
| Selsavage Joseph Anthony (Interim CFO) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Paid exercise price by delivering 6,209 shares
@ $1.14, valued at
$7.1k
|
|
| 08/22/2023 |
4
| Richards William G (Head of Therapeutics Discovery) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Paid exercise price by delivering 8,185 shares
@ $1.14, valued at
$9.3k
|
|
| 08/16/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Sold 40,894 shares
@ $1.319, valued at
$53.9k
Exercised 40,894 options to buy
@ $0.42, valued at
$17.2k
|
|
| 08/11/2023 |
3
| Richards William G (Head of Therapeutics Discovery) has filed a Form 3 on 23andMe Holding Co. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/26/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 07/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 07/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/30/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Sold 40,894 shares
@ $1.7223, valued at
$70.4k
Exercised 40,894 options to buy
@ $0.42, valued at
$17.2k
|
|
| 06/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
8-K
| Cost Associated with Exit or Disposal Activities Interactive Data |
| 06/07/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Granted 43,659 shares
@ $0
Paid exercise price by delivering 15,098 shares
@ $2.08, valued at
$31.4k
|
|
| 06/07/2023 |
4
| Hillan Kenneth J. (Chief Therapeutics Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Granted 44,381 shares
@ $0
Paid exercise price by delivering 15,347 shares
@ $2.08, valued at
$31.9k
|
|
| 06/07/2023 |
4
| Selsavage Joseph Anthony (Interim CFO) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Granted 37,808 shares
@ $0
Paid exercise price by delivering 13,075 shares
@ $2.08, valued at
$27.2k
|
|
| 05/25/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 05/25/2023 |
8-K
| Quarterly results|
Docs:
|
"23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter and full year of fiscal year 2023 , which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired ..." |
|
| 05/23/2023 |
4
| Selsavage Joseph Anthony (Interim CFO) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Paid exercise price by delivering 6,209 shares
@ $1.94, valued at
$12k
|
|
| 05/23/2023 |
4
| Hillan Kenneth J. (Chief Therapeutics Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Paid exercise price by delivering 4,628 shares
@ $1.94, valued at
$9k
|
|
| 05/23/2023 |
4
| HIBBS KATHY L (Chief Administrative Officer) has filed a Form 4 on 23andMe Holding Co.|
Txns:
| Paid exercise price by delivering 4,628 shares
@ $1.94, valued at
$9k
|
|
| 04/17/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|
|
|